In:
British Journal of Haematology, Wiley, Vol. 186, No. 1 ( 2019-07), p. 86-90
Abstract:
Though second allogenic haematopoietic stem cell transplantation ( HSCT ) is considered a curative treatment option after myelodysplastic syndrome ( MDS ) relapse, scant epidemiological data are available. We investigated the outcomes and prognostic factors of second allogenic HSCT in 99 patients with MDS who relapsed after the first HSCT . The median age was 53 years (interquartile; 45–59) and 57 patients (57·6%) were male. Five‐year overall survival was 25·3%. Early relapse (adjusted hazard ratio: 2·78, 95% confidence interval: 1·08–7·21, P = 0·035) and poor performance (3·03, 1·71–5·37, P 〈 0·001) were associated with a significantly poor 5‐year overall survival compared to the other groups ( P 〈 0·001).
Type of Medium:
Online Resource
ISSN:
0007-1048
,
1365-2141
DOI:
10.1111/bjh.2019.186.issue-1
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
1475751-5
Permalink